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Transplantation with autologous hematopoietic progenitors remains an important
consolidation treatment for patients with multiple myeloma (MM) and is thought to prolong
the disease plateau phase by providing intensive cytoreduction. However, transplantation
induces inflammation in the context of profound lymphodepletion that may cause hitherto
unexpected immunological effects. We developed preclinical models of bone marrow
transplantation (BMT) for MM using Vk*MYC myeloma–bearing recipient mice and donor
mice that were myeloma naive or myeloma experienced to simulate autologous
transplantation. Surprisingly, we demonstrated broad induction of T cell–dependent
myeloma control, most efficiently from memory T cells within myeloma-experienced grafts,
but also through priming of naive T cells after BMT. CD8+ T cells from mice with controlled
myeloma had a distinct T cell receptor (TCR) repertoire and higher clonotype overlap
relative to myeloma-free BMT recipients. Furthermore, T cell–dependent myeloma control
could be adoptively transferred to secondary recipients and was myeloma cell clone
specific. Interestingly, donor-derived IL-17A acted directly on myeloma cells expressing the
IL-17 receptor to induce a transcriptional landscape that promoted tumor growth and
immune escape. Conversely, donor IFN-g secretion and signaling were critical to protective
immunity and were profoundly augmented by CD137 agonists. These data provide new
insights into the mechanisms of action of transplantation in myeloma and provide rational
approaches to improving clinical outcomes.
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Introduction
Multiple myeloma (MM) is a bone marrow–based (BM-based) plasma 
cell neoplasm that often evolves from a premalignant stage, known as 
monoclonal gammopathy of undetermined significance (MGUS), to 
present with characteristic features including cytopenias, hypercal-
cemia, lytic bone lesions, and renal impairment (1). The malignant 
plasma cell is clonal and usually generates a monoclonal parapro-
tein that can be quantified in sera and serves as a sensitive disease 
marker. Treatment characteristically involves the administration of 
cycles of immunomodulators and/or a proteosome inhibitor with 
steroids and an alkylating agent until a maximal disease response is 
achieved. At this point, stem cell mobilization, collection, and cryo-
preservation are undertaken, and cells are reinfused after high-dose 
chemotherapy in a therapeutic consolidation step that is known to 
prolong the disease plateau phase, induce higher complete response 
rates, and improve progression-free survival (2, 3). Indeed, stem cell 
transplantation (SCT) remains a standard of care for MM patients 
of appropriate age and performance status (4, 5). The growing num-
ber of patients undergoing SCT in states of minimal residual disease 
(MRD) has resulted in an increasing proportion that enjoy long-term 
complete remission (CR). Intriguingly, survival plateaus that were 
previously only demonstrable in patients with immune-mediated 
graft-versus-myeloma effects after allogeneic SCT are now seen in 
certain subgroups of patients after autologous SCT (6). Nevertheless, 
even in an era of an abundance of new therapeutic agents and SCT, 
resistance to treatment usually ensues, and the majority of patients 
with MM relapse and die of progressive disease.
It is generally presumed that the therapeutic benefit of mye-
loablative chemotherapy and autologous SCT is a result of intensive 
cytoreduction (7). Nevertheless, this therapy invokes significant 
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(Vk12653 clone, unless otherwise stated) were lethally irradiated 
and transplanted with T cell–depleted BM (TCD-BM), without T 
cells (TCD-BMT), or with T cells from myeloma-naive (BMT) or 
myeloma-experienced (BMT+) B6 donors, respectively (see Supple-
mental Figure 1A; supplemental material available online with this 
article; https://doi.org/10.1172/JCI98888DS1). Myeloma burdens 
after BMT were determined by quantifying monoclonal parapro-
tein (M-band) in the sera, expressed as a ratio of γ-globulin/albumin 
(G/A), as previously described (10). The kinetics of M-band pro-
gression was mathematically modeled over time to generate pre-
dictions of myeloma growth as detailed in the Methods. We defined 
a quantitative M-band threshold (G/A = 0.28), at which point all 
animals would reliably develop progressive myeloma. Polyclonal 
plasma cells and monoclonal myeloma cells in the BM and spleens 
of naive and MM-bearing mice, respectively, were classified as 
CD138+CD19–, however, myeloma cells expressed lower levels of 
MHC class II (MHC-II) and higher levels of MHC class I (MHC-I) 
and CD155, and all expressed PD-L1 (Supplemental Figure 1B).
inflammation and profound lymphodepletion that may result in 
unappreciated immunological effects after SCT. To investigate this 
further, we explored the mechanisms of efficacy of SCT in a preclini-
cal model of myeloma using recipient mice bearing Vk*MYC myelo-
ma and radiation-based conditioning with BM as a source of stem 
cells. Although most clinical autologous SCT for myeloma now uti-
lizes high-dose melphalan rather than total body irradiation (TBI), 
this results in similar states of inflammation and lymphodepletion 
(8). Our data provide evidence of the induction of profound T cell–
mediated myeloma control after transplantation and offer therapeu-
tic approaches targeting IL-17A and CD137 costimulation to enhance 
myeloma-immune equilibrium and improve cure rates.
Results
Donor T cells provide immune-mediated control of myeloma after BM 
transplantation. To determine the factors influencing myeloma 
control after BM transplantation (BMT), we developed preclinical 
models (9) in which Vk*MYC myeloma–bearing B6 recipient mice 
Figure 1. Donor T cells provide immune-mediated control of myeloma after BMT. MM-bearing recipients were lethally irradiated and transplanted with 10 × 106 
BM cells with or without 5 × 106 T cells from naive or myeloma-experienced donors. Mice were monitored for survival and tumor burden using M-band (G/A) lev-
els. M-band levels were modeled to calculate a predictive rate of tumor growth (solid line), with shaded CIs and the M-band relapse threshold shown as a dotted 
line. (A) Tumor burden and survival of Vk12653-bearing  recipients (n = 30; combined from 5 experiments) and (B) survival of Vk12598-bearing recipients (n = 10; 
combined from 2 experiments) that received TCD-BMT or BM and T cells from naive donors (BMT). (C) Tumor burden and survival of Vk12653-bearing recipients 
(n = 16–19 combined from 3 experiments) and (D) survival of Vk12598-bearing recipients (n = 12 combined from 2 experiments) transplanted with TCD-BMT, BMT, 
or TCD-BM with myeloma-experienced T cells (BMT+). (E) Tumor burden and survival of Vk12653-bearing recipients treated with saline or CD8- or CD4-depleting 
Abs (αCD8, αCD4) from day 0 to 8 weeks after BMT (n = 11 combined from 2 experiments). (F) Survival of Vk12653-bearing recipients of BMT grafts from NK 
cell–intact (Mcl1fl/fl or WT) or NK cell–deficient (NKp46CreMcl1fl/fl) donors (n = 18 combined from 2 experiments). To determine statistical significance, the tumor 
burden was plotted using longitudinal mixed-effects linear models, and survival was analyzed using a log-rank test. *P < 0.05 and ***P < 0.001.
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recipient mice (Figure 1E), suggesting that both T cell subsets 
play an important role in disease control after BMT. Donor γδ 
and NK T cells were not required for antimyeloma immunity, as 
genetic deletion of these cells (i.e., TCRδ–/– and Jα18–/–, respec-
tively) in donor grafts had no impact on myeloma progression 
(Supplemental Figure 2, A and B). To determine whether NK cells 
provided immunological control of myeloma after BMT, we next 
transplanted grafts from donor mice that lacked the capacity to 
generate mature NK cells (NKp46creMcl1fl/fl; Supplemental Fig-
ure 3A and ref. 11). Surprisingly, we found that NK cell deficiency 
had no impact on myeloma burden (Supplemental Figure 3B) or 
survival (Figure 1F). These results highlight the observation that 
control of myeloma after BMT is not simply a consequence of 
cytoreductive therapy and involves a significant T cell–dependent 
immunological component, consistent with the establishment of 
myeloma-immune equilibrium. Given the susceptibility of Vk*-
MYC myeloma to immune control, we sought to understand the 
nonsynonymous variation among the transplanted MM cells and 
In this preclinical model, we found that MM-bearing recip-
ients of BM and T cells from naive donors (BMT) had signifi-
cantly improved control of both Vk12653 and Vk12598 myeloma 
cell clones compared with recipients of T cell–depleted grafts 
(TCD-BMT), with reduced M-band progression and improved 
survival (Figure 1, A and B). We next compared myeloma pro-
gression in MM-bearing recipients of TCD-BMT, TCD-BM with 
naive T cells (BMT), or T cells from myeloma-experienced donors 
(BMT+). Myeloma-experienced donors had low myeloma burden 
(M-bands <0.28), analogous to the MRD state that is characteris-
tically induced by chemotherapy in patients prior to clinical stem 
cell collection. We observed that control of both myeloma cell 
clones was significantly improved in both BMT and BMT+ recip-
ient mice compared with TCD-BMT recipient mice (Figure 1, C 
and D). Interestingly, we observed no significant difference in 
myeloma control between BMT and BMT+ recipients. Depletion 
of either CD4+ or CD8+ T cells after BMT increased the rate of 
tumor growth and reduced survival compared with saline-treated 
Figure 2. Donor memory T cells limit myeloma progression after BMT with myeloma-experienced T cells. (A) Representative FACS plots and frequency 
of TCM (CD44
+CD62L+) and TEM/EFF (CD44
+CD62L–) cells in naive and myeloma-experienced donor grafts (n = 3 per group). (B–F) MM-bearing recipients were 
lethally irradiated and transplanted with 10 × 106 TCD-BM cells alone (TCD-BMT) or 3 × 106 CD44+ or CD44– T cells from CD45.1/CD45.2 myeloma-experi-
enced donors. (B) Tumor burden, quantified and modeled using M-band levels as described, and survival of Vk12653-bearing recipients (n = 14–16 combined 
from 2 experiments). (C and D) Recipients were sacrificed 2 weeks after BMT
+
, and BM T cells were analyzed by flow cytometry (n = 5 per group from 1 
experiment). (C) Absolute numbers of donor CD8
+
 and CD4 
+
 T cells and TCM and TEM/EFF CD8
+
 T cells in BM. (D) Representative FACS plots and absolute 
numbers of DNAM-1
+
PD-1
+
 and exhausted (DNAM-1–PD-1+TIM-3
+
) donor CD8
+
 T cells. (E and F) Recipients of BMT
+
-CD44
+
 grafts were sacrificed more than 
100 days after BMT
+
, and BM T cells were analyzed via flow cytometry (n = 6 from 1 experiment). (E) Absolute numbers of donor CD8
+
 and CD4
+
 T cells. (F) 
Representative FACS plot and absolute numbers of TCM and TEM/EFF donor CD8
+
 T cells. Data represent the mean ± SEM. *P < 0.05, **P < 0.01, and ***P < 
0.001, by log-rank test for survival data and Mann-Whitney U test for 2-sample and ANOVA for multiple-sample comparisons.
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myeloma-experienced donor (BMT+-CD44+ and BMT+-CD44─, 
respectively). We observed markedly improved myeloma control 
in recipients of BMT+-CD44+ T cells compared with recipients of 
BMT+-CD44─ T cells (Figure 2B), confirming the idea that mem-
ory T cells in the donor graft are the major effectors of myelo-
ma control after BMT with myeloma-experienced donor T cells. 
Interestingly, BMT+-CD44– T cell recipients had improved sur-
vival compared with the TCD-BMT group, demonstrating that 
myeloma-specific priming of naive donor T cells is also an opera-
tive immunological mechanism after BMT.
To further explore the role of preexisting donor myeloma–
specific immunity, we phenotyped donor T cells in the BM of 
recipients 2 weeks after BMT with myeloma-experienced donor 
T cells. We noted a significant increase in CD8+, but not CD4+, 
T cells in recipients of BMT+-CD44+ T cells compared with those 
that received BMT+-CD44– T cells, with expansion of CD8+ T 
effector memory/effector (TEM/EFF) cells in particular at this early 
time point (Figure 2C). Furthermore, this was unique to the BM, 
as CD8+ T cell numbers were equivalent in the spleen (Supple-
mental Figure 4). These changes in CD8+ TEM/EFF cell numbers 
were associated with an increase in the number of activated 
(DNAM-1+PD-1+) CD8+ T cells (15) and a concomitant increase in 
exhausted (DNAM-1–PD-1+TIM-3+) CD8+ T cells (16, 17) in recipi-
ents of BMT+-CD44+ T cells (Figure 2D). These data indicate that 
antimyeloma responses may be amenable to further augmenta-
the recipient mice, since, in patients, a higher mutation burden 
appears to cause susceptibility to immune control but is associat-
ed with a worse clinical outcome (12). We thus performed whole- 
exome sequencing using the translated region, which accounts for 
34,300,425 bp in GRCm38(mm10), as the basis of the assessment 
of variation among tumor and recipient cells. After applying filter-
ing criteria (as outlined in the Supplemental Methods), we noted 
that 950 coding region variants were present, including 375 non-
synonymous variants. These data allowed the direct comparison 
of the burden of nonsynonymous variants in Vk12653 myeloma 
(11.09 per Mb) with 3 published sequencing projects on human 
MM (0.03–20.7 per Mb) (12–14). Given that the Vk12653 burden 
was within the range, albeit in the upper quartile, of that reported 
for human MM, this is a relevant myeloma model.
T cell–dependent myeloma control after BMT with myeloma- 
experienced T cells is the consequence of preexisting myeloma immu-
nity. Next, we investigated whether de novo priming of naive 
donor T cells after BMT or the presence of preexisting T cell anti-
tumor memory in the donor graft contributed to myeloma con-
trol after BMT+. In support of the latter, we observed a significant 
increase in the frequency of CD62L+CD44+ central memory T 
cells (TCM) in myeloma-experienced versus naive grafts (Figure 
2A). To determine the functional relevance of expanded memo-
ry cell populations, we transplanted MM-bearing recipient mice 
with TCD-BM with or without CD44+ or CD44– T cells from a 
Figure 3. BMT generates protective myeloma-specific T cells. MM-bearing recipients were transplanted with TCD-BM from naive mice and either naive T 
cells (naive) or T cells from MM-bearing recipients with long-term control of Vk12653 myeloma (>120 days after BMT: MM-exp). (A) Tumor burden, quanti-
fied and modeled using M-band levels as described, and survival of Vk12653-bearing recipients transplanted with either naive or MM-exp T cells (n = 14–18 
combined from 2 experiments). (B) Representative FACS plots and frequency of TEM/EFF, TCM, and naive CD8+ T cells and (C) representative histograms and 
frequency of CD122+ cells within TCM CD8
+ T cells in the BM of recipients of naive or MM-exp T cells, 120 days after BMT (naive, n = 4; MM-exp, n = 12 from 1 
experiment). (D) Survival of Vk12653-bearing recipient mice and Vk12598-bearing recipient mice transplanted with naive TCD-BM and either naive T cells or 
MM-expT cells from mice with long-term control of Vk12653 myeloma (n = 10 combined from 2 experiments). (E) M-band 6 weeks after BMT of second-
ary recipients of naive TCD-BM and either naive T cells or 2 × 106 MM-exp CD8+ or 2 × 106 MM-exp CD4+ T cells transferred with naive CD4+ or CD8+ T cells, 
respectively (n = 10–11 combined from 2 experiments). Data represent the mean ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001, by Mann-Whitney U test 
for numerical values and log-rank test for survival data.
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the spleen (Supplemental Figure 5). Additionally, we detected an 
increased frequency of antigen-experienced CD122+ T cells (19) 
within the CD8+ TCM population in recipients of MM-exp T cell 
grafts compared with naive grafts (Figure 3C). These data further 
support the idea that expansion of a potentially antigen-specific, 
memory CD8+ T cell population controls myeloma progression. 
To explore this hypothesis, secondary recipient mice were inject-
ed with Vk12653 or Vk12598 myeloma cells and transplanted with 
TCD-BM and either T cells primed against Vk12653 or naive T 
cells. Mice bearing Vk12653 myeloma that were transplanted with 
T cells primed against the same clone had better survival rates 
than did recipients of naive T cells (Figure 3D). However, when 
recipients bearing Vk12598 were transplanted with T cells primed 
against Vk12653, we found that myeloma control was equivalent 
to that of recipients of naive T cells (Figure 3D), suggesting that T 
cell–mediated control of myeloma after BMT is indeed myeloma 
cell clone specific. Interestingly, when MM-exp CD8+ T cells were 
transferred with naive CD4+ T cells, the secondary recipients had 
reduced M-band levels 6 weeks after BMT compared with naive 
control T cells (Figure 3E). However, we found that significant 
protection was not conferred by MM-exp CD4+ T cells transferred 
tion by immune checkpoint blockade after BMT with myeloma- 
experienced donor T cells. Importantly, donor T cells from BMT+-
CD44+ grafts, the majority of which were CD8+, could be recov-
ered in recipient BM more than 100 days after  BMT+ (Figure 2E). 
The CD8+ T cell population included comparable proportions of 
TCM and TEM/EFF cells (Figure 2F), suggesting a contraction of the 
early TEM/EFF expansion to maintain a long-term memory cell pop-
ulation, similar to that seen in acute viral infection (17, 18).
BMT with T cells from naive donors generates myeloma- specific 
T cell memory. To determine whether T cell–mediated control of 
myeloma, generated after BMT by priming naive T cells, was anti-
gen specific and could be transferred to secondary recipients, we 
adoptively transferred T cells from BMT recipients with long-term 
control of disease (>120 days of progression-free survival; MM- 
experienced [MM-exp]). Secondary MM-bearing mice that 
received MM-exp T cells had very limited myeloma progression 
relative to the recipients of naive T cells (Figure 3A). Furthermore, 
late after transplantation, the recipients of MM-exp T cells had a 
significantly increased frequency of CD8+ TCM cells in the BM com-
pared with recipients of naive T cell grafts (Figure 3B). We observed 
no change in the frequency of TCM cells in BM CD4+ T cells or in 
Figure 4. Adoptively transferred CD8+ T cells increase TCRβ repertoire diversity in Vk*MYC nonprogressor mice and exhibit strong clonotypic overlap. 
Adoptively transferred CD8+ T cells (CD45.2) were purified from the spleens of Vk12653-bearing mice with controlled disease (MM-controlled) and MM-free 
transplant control mice (MM-free) for TCRβ deep sequencing (n = 5 per group). (A) Percentage of the TCRβ repertoire based on the frequency of increas-
ing numbers of clonotypes. (B and C) Distribution of rare, small, medium, large and hyperexpanded clonotypes in the TCRβ repertoire. (D) Entropy and 
(E) evenness of the TCRβ repertoire in rare clonotypes. (F) Total unique CDR3 sequences identified in 50,000, 100,000, 250,000, 500,000, and 750,000 
sampled sequences. Residue-identical TCRβ clonotype overlap in (G) rare, (H) small, and (I) medium T cell subsets (n = 5 pairs of mice in each cohort). Data 
represent the mean ± SEM. *P < 0.05, ** P < 0.01, and ***P < 0.001, by unpaired t test.
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with naive CD8+ T cells compared with recipients of naive control 
T cells. These data suggest that CD8+ T cells provide the major 
myeloma-specific immune memory after BMT.
In order to further characterize the generation of T cell–depen-
dent myeloma control after BMT, we performed T cell receptor β 
(TCRβ) deep sequencing of donor CD8+ T cells from mice that 
had controlled MM over the long term (MM-controlled) or from 
MM-free transplant controls (MM-free). The focus on CD8+ T 
cells after BMT was based on the relatively high expression of 
MHC-I versus MHC-II on myeloma cells (Supplemental Figure 
1B), the ability of CD8+ T cells to contribute to myeloma immuni-
ty at steady state (20), and the necessity of MM-exp CD8+ T cells 
to transfer protection to secondary recipients after BMT (Figure 
3E). TCR sequencing revealed a distinct repertoire structure in 
MM-controlled mice compared with MM-free controls. MM-free 
mice exhibited more clonality in the most abundant clonotypes, 
which was significant when sampling the top 5,000 clonotypes 
(Figure 4A). This difference in repertoire composition was further 
validated when partitioning the CD8+ T cell repertoire into rare, 
small, medium, large, and hyperexpanded clonotypes. MM-con-
trolled mice had significantly more of the total repertoire invest-
ed in rare clonotypes and a similar trend for small clonotypes 
(Figure 4, B and C). In MM-controlled mice, this T cell repertoire 
subset also exhibited increased diversity, as seen by an increased 
Shannon entropy score (Figure 4D) and decreased clonality, as 
seen by an increased evenness score (Figure 4E). Additionally, 
the number of unique clonotypes was consistently increased in 
MM-controlled mice over a 50,000–750,000 sequence sampling 
analysis (Figure 4F), and differences in TCR gene usage were also 
observed, with a significant bias toward mTRBV12-1, mTRBV23, 
and mTRBV30 (Supplemental Table 1). We observed no overt dif-
ferences in TRBJ usage or CDR3 length between MM-controlled 
and MM-free mice (data not shown). Importantly, we observed 
significantly higher TCR overlap between MM-controlled mice 
compared with MM-free mice when analyzing the rare, small, 
and medium repertoires (Figure 4, G–I). Given that the MHC-I–
restricted T cell response against tumor antigens is often biased by 
TCRβ chain variable (TRBV) usage and/or involves residue-identi-
cal (public) TCR deployment (reviewed in ref. 21), these data sug-
gest that a significant number of CD8+ T cells in MM-controlled 
mice had expanded against Vk12653 myeloma antigen(s).
IL-17A subverts myeloma-immune equilibrium after BMT. The 
fact that CD4+ T cells controlled myeloma despite its very low 
expression of MHC-II suggests that these CD4+ T cells may act 
Figure 5. Donor-derived IL-17A promotes myeloma relapse after BMT. (A) Tumor burden, quantified and modeled using M-band levels as described, and 
survival in MM-bearing recipients transplanted with BM and T cells from WT or IL-17A–deficient (IL-17A–/–) donors (n = 20 combined from 4 experiments). (B) 
M-band of MM-bearing BMT+ with myeloma-experienced donors that were treated twice a week with 150 μg i.p of an IL-17A–blocking Ab or isotype control (cIg) 
from day 0 to week 6 after BMT+ (n = 12–13 combined from 2 experiments). (C–E) MM-free and MM-bearing recipient mice were transplanted with BM and T 
cells from IL-17ACreRosa26eYFP donors. eYFP+ cells were analyzed in BM (femur) and spleens 6 weeks after BMT. Representative dot plot (concatenated BM) 
and (C) total eYFP+ frequency and numbers, (D) frequency of TCRγδ+ and TCRβ+ cells within the eYFP+ cell population, and (E) total numbers of Th17 (eYFP+ 
TCRβ+CD4+) and Tc17 (eYFP+TCRβ+CD8+) cells (n = 9 combined from 2 experiments). Data represent the mean ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001,  
by log-rank test for survival and Mann-Whitney U test for numerical values.
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via the release of soluble factors during T cell differentiation, 
independently of cognate TCR–MHC-II interactions with myelo-
ma targets. We first investigated whether Th17 immunity played 
a role in myeloma relapse after BMT, since IL-17 has been sug-
gested to be involved in myeloma progression (22, 23). We found 
that IL-17A deficiency in donor grafts significantly improved 
myeloma control after BMT (Figure 5A). We used the BMT mod-
el to address this, as the growth of myeloma was modified in a 
number of naive knockout donor strains, preventing the use of 
these mice as myeloma-experienced donors. Nevertheless, inhi-
bition of IL-17A with a mAb also improved myeloma control after 
BMT from myeloma-experienced donors (Figure 5B). Deficiency 
of donor-derived IL-6, a cytokine known to promote Th17 differ-
entiation (24) and a known growth factor for myeloma (25), also 
improved myeloma control after BMT (Supplemental Figure 6A). 
However, this effect of IL-6 was probably due to direct effects on 
myeloma growth, as Th17 differentiation remained largely intact 
(Supplemental Figure 6B), given the known ability of recipient 
cells to generate IL-6 after transplantation and drive Th17 differ-
entiation (26). Indeed, the importance of recipient-derived IL-6 
was confirmed by the inability of myeloma to progress when both 
the recipient and donor were IL-6 deficient (Supplemental Fig-
ure 6C). In concert, Vk*MYC myeloma cells expressed the IL-6 
receptor and the coreceptor Gp130 (Supplemental Figure 6D) 
and phosphorylated STAT3 in response to IL-6 (Supplemental 
Figure 6E), consistent with expression of the IL-6 signaling com-
plex on primary myeloma patients’ samples (27). To determine 
whether myeloma itself could influence type 17 polarization, we 
used IL-17A fate-mapped reporter donors (IL-17CreRosa26eYFP), 
in which enhanced YFP (eYFP) is permanently expressed in cells 
that have ever produced IL-17A, regardless of continued IL-17A 
gene transcription (28). While we noted a trend toward increased 
eYFP+ cell frequency in the BM of MM-bearing mice (P = 0.06), 
we noted a small decrease in the overall number due to impaired 
hematopoiesis in the MM-bearing mice (Figure 5C). We detected 
no change in the frequency of eYFP+ cells in the spleen; howev-
er, eYFP+ cell numbers were significantly increased as a result of 
splenomegaly in the MM-bearing-mice (Figure 5C). Within the 
eYFP+ cell population in mice bearing myeloma, an expansion 
of TCRβ+ relative to TCRγδ+ T cells was seen in the BM (Figure 
5D). The majority of eYFP+TCRβ+ cells were CD4+ T cells (Th17), 
although myeloma also induced a small but significant expan-
sion of CD8+ T cells (Tc17) (Figure 5E). We next investigated 
cytokine production by eYFP+ cells in the spleens of MM-bearing 
and MM-free mice after BMT. As expected, we found that the 
majority of eYFP+ cells had significant IL-17A production, and 
similar levels of TNF, GM-CSF, IFN-γ, and IL-22 were also seen 
in MM-free and MM-bearing mice (Supplemental Figure 7). Tak-
en together, these data suggest that, although myeloma has lim-
ited influence on donor Th17 differentiation per se, donor IL-17A 
secretion is demonstrable after BMT and is sufficient to promote 
myeloma progression.
Donor-derived IL-17A acts directly on myeloma cells to promote 
progression after BMT. Given the observed role of donor-derived 
IL-17A in subverting myeloma-immune equilibrium after BMT, 
we investigated whether donor or recipient compartments were 
responding to IL-17A to mediate this effect. We thus transplant-
ed grafts that were deficient in a critical IL-17A signaling recep-
tor subunit (IL-17RC–/–) and noted myeloma progression similar 
to that seen when donor grafts were WT (Figure 6A). Interest-
ingly, there was a small but nonsignificant increase in the num-
ber of recipients of IL-17RC–/– grafts that entered the plateau 
phase late after BMT. Nonetheless, these data clearly demon-
strate that IL-17A was acting directly on the recipient compart-
ment, putatively BM stroma or myeloma itself, since the latter 
also expressed high levels of the IL-17A receptor (Figure 6B). To 
distinguish these possibilities, we used IL-17R subunit A–defi-
cient (IL-17RA–/–) mice as both recipients and donors, such that 
IL-17A could only signal in myeloma cells. Given the known 
Figure 6. Donor-derived IL-17A acts directly on myeloma cells to promote 
progression. (A) Tumor burden, quantified and modeled using M-band 
levels as described, and survival of MM-bearing recipients transplanted 
with BM and T cells from B6.WT or B6.IL-17 receptor subunit C–deficient 
(IL-17RC–/–) donors (n = 23 combined from 3 experiments). (B) IL-17RA (red, 
with isotype in gray) expression on VK12653 myeloma cells harvested from 
the BM and spleens of MM-bearing mice. (C and D) MM-bearing WT recip-
ient mice were transplanted with WT grafts, while MM-bearing IL-17RA–/– 
mice were transplanted with IL-17RA–/– grafts. All recipient mice were 
cohoused for 4 weeks prior to BMT. (C) Serum levels of IL-17A (week 2, n = 
6; week 4, n = 9–10; week 6, n = 3–5) and (D) survival (n = 11 combined from 
2 experiments). Data represent the mean ± SEM. *P < 0.05, **P < 0.01, and 
***P < 0.001, by log-rank test for survival data and Mann-Whitney U test 
for numerical values.
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A role for IL-17A as a myeloma growth factor has not been 
examined after BMT, and so we next determined the effects of 
IL-17A signaling on myeloma cells in vivo. To limit contributions 
of endogenous T cell–derived IL-17A, we treated MM-bearing 
Rag2γc–/– mice with exogenous recombinant mouse IL-17A or 
saline and collected myeloma cells thereafter for RNA-Seq. We 
detected clear differences in the transcriptome of myeloma 
cells exposed to IL-17A in vivo (Figure 7A). We identified 381 
dysbiosis in these mice, all recipient mice were cohoused for 
4 weeks prior to BMT to equilibrate their gastrointestinal 
microbiomes (29). In the absence of IL-17A signaling and sub-
sequent consumption, systemic IL-17A levels were elevated 
in the IL-17RA–/– → IL-17RA–/– recipient mice (Figure 6C), and 
myeloma developed rapidly in these mice (Figure 6D), confirm-
ing that direct signaling to myeloma cells by IL-17A does in fact 
drive myeloma progression.
Figure 7. Gene expression profiling of IL-17A–treated Vk*MYC myeloma. Splenic Vk12653 myeloma cells were harvested from Ragγc–/– mice treated 
with IL-17A or saline, and RNA-Seq was performed. (A) Principal component analysis (PCA) plot of the replicate samples from IL-17A–treated (n = 4) 
and saline-treated (n = 3) groups. (B) Heatmap of 50 genes and (C) volcano plot of genes that were differentially expressed between the IL-17A– and 
saline-treated groups. (D and E) GSEA of differentially expressed genes was determined by querying the MSigDB. (D) Summary of differentially expressed 
pathways. The red dotted line is drawn at a FDR of 0.05, and the shaded areas denote normalized enrichment scores (NES) between –2 and +2. (E) Enrich-
ment plot for a set of genes with promoters bound by E2F4 and enrichment plot for genes involved in antigen processing and presentation and leukocyte 
migration and activation. P < 0.05, FDR <0.2; NES >1.75 and <1.75. The P value for a GSEA analysis was calculated using the Kolmogorov-Smirnov statistics 
comparing ranks of P values of genes in the gene set versus uniform distribution.
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Database (MSigDB) (Figure 7D). Gene set enrichment anal-
ysis (GSEA) of the transcriptome of IL-17A–treated myeloma 
revealed 21 significantly altered pathways (FDR <0.05) includ-
ing those involved in cell cycling, metabolism, proliferation, 
and migration. Of note, a set of genes with promoters bound 
by E2F4, which promotes proliferation in cancer cells (33), was 
upregulated in response to IL-17A (Figure 7E). Furthermore, 
genes related to antigen processing and presentation and leu-
kocyte trafficking and activation (34) were downregulated in 
response to IL-17A (Figure 7E). Thus, donor-derived IL-17A 
drives intrinsic myeloma progression directly after BMT, inde-
pendent of T cell immunity, highlighting IL-17A as a potential 
therapeutic target.
Donor IFN-γ secretion and signaling control myeloma after BMT 
and can be augmented by agonistic CD137 Ab treatment. Given 
the importance of Th1 immunity in tumor control, we next ana-
lyzed IFN-γ secretion by CD8+ T cells after BMT in mice in which 
myeloma had relapsed (MM-relapsed) or was being controlled 
(MM-controlled) or in mice that were transplanted in the absence 
of myeloma altogether (MM-free). While IFN-γ production from 
CD4+ T cells was unaffected by MM-relapse after BMT (data not 
shown), these mice had impaired IFN-γ secretion (Figure 8, A and 
B) and reduced total numbers of IFN-γ–secreting CD8+ T cells 
relative to numbers in MM-controlled and MM-free mice (Figure 
8C). In order to understand the functional consequences of this, 
we used IFN-γ–deficient (IFN-γ–/–) and IFN-γ receptor–deficient 
(IFN-γR–/–) grafts in our transplant systems. Critically, recipients 
of both graft types rapidly developed myeloma, which indicated 
a crucial role for donor-derived IFN-γ generation and signaling in 
the immune equilibrium seen after BMT (Figure 8D).
differentially expressed genes with a P value of less than 0.05, 
of which 11 were significantly different after FDR correction 
(Figure 7, B and C, and Table 1). Interestingly, Plagl2, which 
was upregulated with IL-17A treatment, has been shown to pro-
mote cell proliferation in leukemia (30, 31), and Spns, which 
was downregulated with IL-17A treatment, has been shown to 
impair STAT3-mediated prosurvival pathways in lung cancer 
(32). Taken together, this suggests that IL-17A may promote the 
survival and proliferation of myeloma cells. To characterize the 
pathways affected in myeloma by IL-17A treatment, we queried 
up- and downregulated genes against the Molecular Signatures 
Table 1. Selected significantly altered genes (FDR <0.05) in 
Vk*MYC myeloma after treatment with IL-17A
Gene Fold change (log) FDR Function/role
Decreased with IL-17A treatment
Napsa –2.18 9.4 × 10–05 Protein metabolism
Spns2 –2.14 2.0 × 10–03 Lymphocyte trafficking
Aldh2 –1.98 5.0 × 10–08 Enzyme, oxidative pathway
Mpeg1 –1.78 9.4 × 10–05 Membrane pore formation
Ceacam1 –1.77 3.6 × 10–03 Adhesion molecule 
Cd53 –1.62 3.4 × 10–03 Regulation of cell growth and motility 
Id2 –1.04 4.4 × 10–02 Transcriptional regulator
Increased with IL-17A treatment
Gcap14 0.728 2.7 × 10–02 Cell proliferation and differentiation
Plagl2 0.768 4.4 × 10–02 Transcriptional activator
Cpeb2 0.906 2.2 × 10–02 Cell-cycle progression
Figure 8. Immunological control of myeloma is IFN-γ dependent. (A–C) MM-bearing or MM-free B6.WT mice were transplanted as previously described, 
and IFN-γ production was determined ex vivo 8 weeks later. (A) Representative histograms, (B) geometric MFI, and (C) absolute numbers of IFN-γ–produc-
ing CD8+ T cells in mice with active myeloma progression (MM-relapsed) or controlled disease (MM-controlled) and in transplant control mice (MM-free) 
(MFI, n = 5–10 from 2 experiments; absolute number, n = 7–12 combined from 3 experiments). (D) Tumor burden and survival of MM-bearing recipient mice 
transplanted with BM and T cells from B6.WT, B6.IFN-γ–/–, or B6.IFN-γR–/– donors (n = 20 combined from 4 experiments). Data represent the mean ± SEM. 
*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, by log-rank test for survival data and Mann-Whitney U test for 2-sample and ANOVA for multiple- 
sample comparisons.
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PD-1 and TIM-3, which are early features of exhaustion that are most 
appreciable and defined by t-distributed stochastic neighbor embed-
ding (t-SNE) analysis (Figure 10, D and E). Importantly, we found 
that exhaustion was not an irreversible phenotype, as determined by 
the absence of CD101 and CD38 coexpression (36) (Figure 10E). We 
thus reasoned that PD-1 inhibition would further augment the pro-
tective effect of CD137 agonists in MM-bearing BMT+ recipients. In 
these experiments, we transplanted lower doses of donor T cells and 
started PD-1 inhibition treatment 10 days after CD137 administration 
(Figure 10F). This short-term PD-1 inhibition, late after BMT+, had no 
effect on myeloma burden in isolation. Treatment with CD137 alone 
resulted in stabilization of myeloma burden, while disease burden 
in the isotype control group had progressed by 4 weeks after  BMT+. 
The mice treated with the combination of CD137 mAb and anti–PD-1 
showed dramatic control of myeloma, and there was a reduction in 
myeloma burden from week 2 to week 4 after  BMT+, consistent with 
active antimyeloma immunity (Figure 10F). Thus, administration of 
CD137 agonists in combination with PD-1 blockade early after BMT, 
when IFN-γ and T cell–mediated immunological control have been 
initiated, represents an attractive approach to improve the depth and 
length of remission after transplantation.
The importance of Th1/Tc1 immunity in the control of myelo-
ma led us to explore the ability of agents that might further expand 
this pathway. CD137 (4-IBB) agonists have proven effective in this 
regard and are entering clinical trials (20, 35). Thus, we administered 
a CD137 agonistic mAb for 4 weeks, commencing 2 weeks after trans-
plantation, when myeloma was in a state of MRD (Figure 9A). This 
resulted in a dramatic improvement in myeloma control as demon-
strated by reductions in M-band levels, improved survival, and com-
plete eradication of myeloma from the BM (Figure 9, B–D). Important-
ly, CD137 agonist administration increased T cell numbers in BM, but 
not the spleen, while reducing the proportions of Tregs in the CD4+ T 
cell compartment (Figure 9E). Finally, CD8+ TEFF cell frequency and 
function, as determined by KLRG1 (Figure 9F), granzyme B (GrB), 
and IFN-γ expression, were also increased in the BM (Figure 9G), 
consistent with the profound immune-driven control of myeloma. 
Similar effects of CD137 agonist administration were observed after 
BMT with myeloma-experienced donors, with decreased M-band, 
increased numbers of CD8+ and CD4+ T cells, and increased num-
bers of KLRG1+, Ki67+, GrB+, CD107a+, IFN-γ+, and TNF+CD8+ T cells 
in the BM of Ab-treated recipients (Figure 10, A–C). However, this 
increase in CD8+ TEFF function was associated with an upregulation of 
Figure 9. CD137 costimulation promotes long-term eradication of myeloma after BMT. MM-bearing recipient mice were transplanted with BM and T cells 
from B6.WT donors. Agonistic CD137 (clone 3H3) or a control mAb (IgG2a) was administered from week 2 to week 6 after BMT. (A) Illustration of experi-
mental design. (B) Tumor burden, quantified using M-band levels as described, and (C) overall survival (n = 18 combined from 2 experiments). (D–G) BM 
and spleens were harvested after treatment ceased, and cells were analyzed using flow cytometry (n = 5–10 from 1 to 2 experiments). (D) Percentage of 
CD138+CD19– myeloma cells in BM. (E) Absolute numbers of CD3+, CD8+, and CD4+ T cells and frequency of FoxP3+ within CD4+ T cells in BM and spleens. (F) 
Representative histograms show KLRG1 expression in CD8+ T cells and absolute numbers of KLRG1+ cells within CD8+ and CD4+ T cells in BM. (G) Repre-
sentative histograms show GrB, IFN-γ, and CD107a expression in CD8+ T cells and graphs show absolute numbers of GrB+, IFN-γ+, and CD107a+CD8+ T cells 
and GrB+ and IFN-γ+CD4+ T cells in BM. Data represent the mean ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001, by log-rank test for survival data and 
Mann-Whitney U test for numerical values.
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scape characterized by an accumulation of genetic defects (38), 
it is also consistent with (and not mutually exclusive to) the 
well-described characteristic of immunological tumor escape 
(39, 40). Finally, myeloma itself is associated with immune 
defects that may contribute to disease penetrance (41). To date, 
NK cells have been identified as key mediators of antimyeloma 
effects, especially following treatment with immunomodulatory 
drugs (IMiDs) (42–44). Expanded T cell populations bearing spe-
cific TCR-Vβ families, as assessed by flow cytometry, have been 
observed in myeloma patients with long-term control of disease 
(45, 46), and T cells from the BM of myeloma patients have been 
shown to respond to autologous tumor presented by dendritic 
cells in vitro (47, 48). However, these studies were performed in 
patients undergoing treatment with IMiDs, which are known to 
expand T cell clones (49), and it is unclear whether these changes 
in the T cell repertoire are generated in response to the myeloma 
or whether the T cells have myeloma-specific immunity. These 
clinical findings are, by nature, observational, and studies in the 
clinically relevant transplantation models described here are 
required to delineate true cause and effect.
Discussion
Autologous SCT remains the standard consolidation treatment 
for patients with myeloma, and the development of strategies to 
increase the depth and duration of response remains a critical 
clinical objective. Here, we demonstrate a hitherto unappreciat-
ed and potent T cell–mediated process of immune control after 
transplantation that indicates the reestablishment of a state of 
myeloma- immune equilibrium. We show that this process involves 
clonotypic donor CD8+ T cell expansion and demonstrate T cell–
mediated and antigen-specific myeloma control in secondary 
recipients. Importantly, Th17 differentiation impairs this process 
via the direct action of IL-17A on myeloma cells, while IFN-γ secre-
tion and signaling in donor graft are critical for myeloma-specific 
immunity, which can be enhanced via CD137 costimulation.
Currently, there is clear but indirect evidence for immune- 
mediated control of myeloma. First, a cohort of patients who 
entered SCT while in CR achieved long-term survival there-
after (6), consistent with the immune control most commonly 
ascribed to allogeneic SCT (37). Second, while the progression 
of long-standing MGUS to active myeloma occurs within a land-
Figure 10. CD137 costimulation is augmented by PD-1 blockade after BMT with myeloma-experienced T cells. MM-bearing recipient mice were trans-
planted with naive TCD-BM and T cells from myeloma-experienced donors. Agonistic CD137 (clone 3H3) or a control mAb (IgG2a) was administered from 
week 1 to week 5 after BMT+. (A) Tumor burden, quantified using M-band levels as described (n = 10 combined from 2 experiments). (B–F) BM was harvest-
ed after treatment ceased, and cells were analyzed using flow cytometry (n = 8–10, from 1 experiment). (B) Absolute numbers of CD8+ T and CD4+ T cells 
in BM. (C) Absolute numbers of KLRG1+, Ki67+, GrB+, IFN-γ+, TNF+, and CD107a+CD8+ T cells in BM. (D) tSNE analysis and heatmaps of median CD8+ T cell 
exhaustion marker coexpression. (E) CD8+ T cell exhaustion marker quantification. (F) Experimental design and M-band levels of MM-bearing recipients 
transplanted with 1 × 106 myeloma-experienced T cells and 10 × 106  naive TCD-BM cells and treated with CD137 mAb alone (from day 7), anti–PD-1 alone 
(from day 17), CD137 mAb plus anti–PD-1, or isotype control (cIg). Data represent the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, 
by Mann-Whitney U test for 2-sample and ANOVA for multiple-sample comparisons.
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ferentiation has been reported as both unaffected (22) and reduced 
in patients with myeloma relative to healthy controls (55). Primary 
clinical myeloma samples are known to express the IL-17R (22), 
as does Vk*MYC myeloma, and myeloma is thus able to respond 
to IL-17A directly. Experiments culturing myeloma cell lines with 
exogenous IL-17A in vitro suggest that IL-17A may promote cell 
growth, however, attempts to address this in vivo have only been 
performed in immunocompromised mice with s.c. tumors (22). 
Additional studies suggest that myeloma itself produces IL-17A 
that acts on BM stromal cells to produce IL-6, raising the possibil-
ity that myeloma-derived IL-17A acts in a paracrine fashion (23). 
In contrast, we have shown that, after transplantation, IL-17A is 
produced by donor T cells and acts directly on myeloma cells, inde-
pendent of effects on nonmalignant donor or host tissue. Impor-
tantly, we demonstrate that IL-17A signaling in myeloma results 
in significant prosurvival transcriptional activity, although we 
could not see amplification of IL-6 mRNA as part of this response. 
It should be noted that we have not excluded the possibility of an 
additional role for IL-17A secretion and paracrine signaling in MM 
and that the two mechanisms are not mutually exclusive.
The immunological control of most tumors has been defined 
as a Th/Tc1 process, in which  IFN-γ secretion and signaling are 
pivotal (39, 40). Indeed, initial studies in vitro demonstrated 
that IFN-γ inhibits myeloma cell growth (56) and, in vivo, Vk*-
MYC myeloma results in accelerated lethality in IFN-γ–/– mice 
(20). Importantly, IFN-γ production by PBMCs appears similar in 
patients with various stages of MM and in healthy controls (57). 
Surprisingly, given the nature of the disease, IFN-γ production 
by T cells has not been well described in the BM tumor microen-
vironment of patients with MM. We observed that CD8+ T cells 
from transplanted mice with progressive myeloma had impaired 
IFN-γ production, while it was unaffected in those with controlled 
myeloma. Consistent with this, agonistic CD137 mAb eradicated 
myeloma in the majority of transplanted animals by increasing 
Th1/Tc1 expansion, consistent with the known antitumor activity 
of IFN-γ in cancer models (20, 58–60). The antimyeloma activity 
of CD137 agonists has been reported in preclinical nontransplant 
settings (20, 60), and a phase I trial (NCT02252263) has recent-
ly been completed, however, no results have been reported to 
date. Importantly, our study suggests that CD137 agonists could 
be used in combination with autologous SCT to improve clinical 
outcomes. Furthermore, our data highlight the finding that a com-
bination approach using CD137 agonists and PD-1 inhibition may 
further improve clinical outcomes after autologous SCT.
We believe our study has major implications for how myelo-
ma might be optimally treated. First, clinical data, although retro-
spective and registry based, suggest that outcomes for myeloma 
after syngeneic transplantation are superior to those after autolo-
gous transplantation (61, 62). While this may theoretically reflect 
a benefit from using a graft free of contamination by myeloma 
cells, studies purging grafts to eliminate contamination have not 
improved outcomes (63–65), and gene-marking studies have not 
shown relapse to be derived from myeloma cell contamination 
within the graft, at least as a common event (66). More likely, 
then, the transplantation of a fully immunologically competent 
syngeneic graft is responsible for this effect, such that the trans-
planted immune system is free from any prior exposure to cytore-
In nontransplant preclinical models, T cells and NK cells have 
been implicated in myeloma progression in mice bearing Vk*MYC 
myeloma (20). Importantly, it cannot be assumed that immunity 
in nontransplant and transplant settings is equivalent. The gen-
eration of murine models of BMT can never completely recapit-
ulate the entire clinical scenario. In particular, we cannot harvest 
marrow (or acquire adequate numbers of peripheral blood stem 
cells) from a mouse as a live procedure, but the value of working 
with inbred mice means this is not required to transplant immu-
nologically identical grafts. Transplantation induces a profound 
inflammatory response, extensive myeloma cell death with sub-
sequent MRD states, and a profound state of lymphodepletion, 
which is permissive of rapid proliferation and differentiation of 
transplanted donor T cells. To date, the beneficial outcomes of 
autologous SCT have been largely attributed to cytoreduction. 
Our study reveals a potent immunological aspect of transplanta-
tion, namely, the protective myeloma immunity driven by trans-
planted T cells rather than NK cells, either within the transplanted 
donor memory T cell fraction, or after transplantation within the 
naive T cell fraction. Importantly, the use of a MM-free transplant 
control in our TCR repertoire study provides critical evidence that 
changes in the T cell repertoire of mice with well-controlled dis-
ease were generated specifically in response to myeloma. Myelo-
ma increased TCR diversity in the lower-abundance CD8+ T cell 
compartment and significantly increased the overlap of shared 
clonotypes in the rare, small, and medium compartments. This is 
strong evidence for the generation of antigen-specific CD8+ T cell 
memory for myeloma antigens in mice with controlled disease. 
Furthermore, adoptive transfer experiments using T cells from 
these mice showed that there is a functional memory response 
and that this response is Vk*MYC clone specific and is in fact con-
ferred by CD8+ T cells. Thus, we believe the present study provides 
new and definitive evidence for the establishment of antigen-spe-
cific, T cell–dependent myeloma control after BMT and shows the 
critical relationship to transplanted T cell subsets, the clinically 
important effect of prior exposure to myeloma, T cell clonality, 
and, finally, differentiation. Importantly, we also define methods 
to improve this process of active control after transplantation by 
driving IFN-γ–dependent T cell responses with αCD137-based 
immunotherapy and IL-17A inhibition.
In support of this concept of immunological control, we have 
recently demonstrated that myeloma progression after BMT is 
associated with CD8+ T cell exhaustion and may be prevented by 
T cell Ig and ITIM domain (TIGIT) blockade (50). Together, these 
studies define an important new concept that SCT for myeloma 
is probably more than just cytoreduction and provide rational 
immune-based interventions that require testing, with the aim of 
improving post-BMT clinical outcomes for patients.
The role of T cell differentiation and cytokine production in 
myeloma control is unclear, and a consensus has not been reached, 
particularly regarding the role of Th17 differentiation. Th17 differ-
entiation is driven by IL-6 signaling, which is supported by oth-
er cytokines (e.g., IL-21 and IL-23) (51). IL-6 is known to act as a 
myeloma growth factor and is dysregulated in patients undergoing 
transplantation (40, 52). Clinical studies have shown elevated lev-
els of IL-17A in the sera of patients with myeloma (53), a finding that 
has been linked to angiogenesis (54). Paradoxically, then, Th17 dif-
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(IL-6R, clone D77ISA7) were purchased from eBioscience. PerCp-
Cy5.5-conjugated Ab against CD8 (clone 53-6.7); PE-conjugated Ab 
against STAT3 (4/0-STAT3); and violet 450–conjugated Abs against 
CD107a (clone 1D4B) and rat IgG2a isotype control were purchased 
from BD Biosciences. PE-conjugated Ab against Gp130 (clone 125623) 
was purchased from R&D Systems. FITC-conjugated Ab against CD4 
(clone GK1.5) was produced in house from hybridoma supernatant.
Preclinical models of BMT using recipients bearing Vk*MYC myeloma. 
Vk*MYC myeloma clones Vk12653 and Vk12598, which originate from 
Vk*MYC-transgenic mice and produce diverse monoclonal parapro-
tein (9), were provided by Marta Chesi (Mayo Clinic, Scottsdale, Ari-
zona, USA). For subsequent experiments, myeloma cell clones were 
propagated in house in B6.WT and RAGγc–/– mice, respectively. Trans-
plantable VK12653 and Vk12598 myeloma cell clones have been shown 
to have immunological outcomes similar to those of spontaneous- onset 
myeloma in Vk*MYC-transgenic mice (70). Recipient mice (hereaf-
ter referred to as MM-bearing mice) were injected i.v. with Vk*MYC 
myeloma cells 14 days prior to BMT and 21 days prior to BMT+ (1 × 106 
CD138+CD19– cells; Vk12653, unless otherwise stated). MM-bearing 
recipient mice were transplanted as described previously (71). In brief, 
on day 1, recipient mice received 1,000 cGy total body irradiation (TBI) 
(137Cs source at 81 cGy/min), and on day 0, they transplanted with 10 × 
106 BM or T cell–depleted BM (TCD-BM) from B6.WT or transgenic 
(on a B6 background) donors with or without 5 × 106 purified splenic 
CD3+ T cells (purity >80%; using magnetic bead depletion) for BMT 
or 5 × 106 sorted CD3+ T cells (purity >99%) from donors from the con-
current recipient cohort for BMT+. BM was depleted of T cells (TCD) 
using an Ab master mix against CD4, CD8, and CD90.2 and rabbit 
complement (Cedarlane Laboratories Ltd.) as described previously 
(72). Purified myeloma-experienced splenic CD3+ T cells from CD45.1/
CD45.2 mice were stained with CD44 and CD62L and sorted via flow 
cytometry for BMT+ experiments with CD44+ and CD44– T cell grafts. 
Recipients were bled every 2 weeks, and serum samples were analyzed 
using a Sebia Hydrasys serum protein electrophoresis system to quan-
tify paraprotein as a G/A ratio (referred to as M-band), as previously 
described (73). Transplanted mice were monitored daily, up to 120 
days, and sacrificed when clinical scores reached 6 or higher (described 
in ref. 74) or hind limb paralysis occurred. Anti-CD4–depleting 
Abs (GK1.5, purified from hybridoma supernatants, 500 μg/mouse, 
i.p., on day 0 and then 250 μg/mouse, i.p., thereafter) or anti-CD8–
depleting Abs (53.5.8, purified from hybridoma supernatants, 150 μg/
mouse, i.p.) were administered once a week from day 0 until 8 weeks 
after  BMT. IL-17A mAb (M210, murinized form, Amgen) was adminis-
tered twice a week for 6 weeks after BMT+ from day 0 (150 μg/mouse, 
i.p.). Agonistic CD137 mAb (clone 3H3, Bio X Cell) or control rat IgG2a 
Ab (provided by MJS) was administrated twice weekly from weeks 2 to 
6 after BMT or from weeks 1 to 5 after  BMT+ (100 μg/mouse, i.p.). The 
myeloma-experienced T cell dose was reduced to 1 × 106 cells for the 
CD137 and anti–PD-1 combination experiment. Anti–PD-1 (RMP1-14, 
Bio X Cell) or rat IgG2a (Mac4, purified from hybridoma super natants) 
was administered twice weekly with CD137 from day 17 to day 28 
(100 μg/mouse, i.p.).
Adoptive transfer. Secondary recipient mice were injected with 
either Vk12598 or Vk12653 myeloma cells and transplanted with 10 × 
106 TCD-BM (naive B6.WT) and 5 × 106 CD3+ T cells or 2 × 106 CD4+ 
and 2 × 106 CD8+ T cells primed against Vk12653 or naive T cells (B6.
WT). CD3+ T cells were isolated using magnetic bead depletion, and 
ductive and immunosuppressive agents, a scenario that is replicat-
ed in our murine model, in which BM grafts were harvested from 
immunogenically identical but untreated donors. Additionally, 
the presence of preexisting myeloma-specific T cells in the mem-
ory compartment of myeloma-experienced donor grafts provides 
support for immunologically focused studies of induction reg-
imens permissive of immune competence prior to stem cell col-
lection, with a correlation to immunological and clinical outcomes 
thereafter. Second, preventing IL-17A signaling to myeloma cells 
could improve transplantation outcomes, and anti–IL-17A Abs are 
already available for the treatment of other inflammatory diseases 
(67–69). Finally, with the availability of multiple PD-1 inhibitors 
and 2 humanized agonistic CD137 mAbs, urelumab (Bristol-My-
ers Squibb, e.g., NCT02252263) and PF-05082566 (Pfizer), 
treatment with anti-CD137 and anti–PD-1 after autologous SCT, 
when in a state of MRD, could provide a novel means of improving 
immune-based cures for patients.
Methods
Mice. Female, 8- to 12-week-old C57BL/6 (B6.WT; CD45.2) and B6.Sjl.
PTPRCA (CD45.1) mice were purchased from the Animal Resources 
Center (Perth, Western Australia, Australia). B6.45.1/45.2 mice and 
knockout mice on a B6 background: B6.IL-17RC–/– and B6.IL-17RA–/– 
(Amgen); B6.IL-17A–/– (provided by Y. Iwakura, The University of 
Tokyo, Tokyo, Japan); B6.IFN-γ–/– and B6.IFN-γR–/– (The Jackson Lab-
oratory); and B6.Jα18–/– (Peter Mac [Peter MacCallum Cancer Cen-
tre], East Melbourne, Victoria, Australia); B6.IL-6–/– (provided by S. 
Alexander, University of Sydney, New South Wales, Australia); and 
reporter B6.IL-17CreRosa26YFP (described in ref. 28) mice were bred 
in-house (QIMR Berghofer Medical Research Institute). NKp46Cre 
Mcl1fl/fl (Mcl1fl/fl mice were generated by Nicholas Huntington [ref. 
11]), TCRδ–/–, and RAGγc–/– mice were produced in house. Mice were 
housed in sterilized microisolator cages and received acidified (pH 
2.5), autoclaved water and normal chow. For cohousing experiments, 
mice were housed in large cages for 4 weeks prior to transplantation 
and for the duration of the experiment after transplantation.
Abs. The following Abs used in this study were purchased from 
BioLegend: FITC-conjugated Ab against I-A/I-E (M5/114.15.2); phy-
coerythrin-conjugated (PE-conjugated) Abs against CD155 (4.24.1), 
NKp46 (29A1.4), IL-22 (poly5164), CD45.1 (A20), and rat IgG2a 
isotype control; PE-Cy7–conjugated PD-1 (RMP1-30) and rat IgG2b 
Ab; Alexa Fluor 647–conjugated Abs against H-2Db (KH95), CD101 
(RM101), and CD226 (TX42.1); Alexa Fluor 700–conjugated Abs 
against CD45.2 (clone 104), Ki67 (clone 16A8), CD62L (clone MEL-
14), and IL-17A (clone TC11-8H10.1); allophycocyanin-conjugated 
(APC-conjugated) Abs against PD-L1 (CD274, clone 10F.9G2), KLRG1 
(clone 2F1), GrB (clone GB12), TNF (clone MP6-XT22), TCRβ (clone 
H57-597), and Syrian hamster IgG, mouse IgG1, and rat IgG2b iso-
type controls; APC-Cy7–conjugated Abs against CD19 (clone 6D5), 
CD38 (clone 90), and CD8 (clone 53-6.7); PerCpCy5.5-conjugated 
Abs against CD122 (clone TM-β1) and GM-CSF (clone MP1-22E9); 
brilliant violet 421–conjugated Abs against CD138 (clone 281-2), 
IFN-γ (clone XMG1.2), CD44 (clone IM7), PD-1 (clone 29F.1A12), 
yδ-TCR (clone GL3), and rat IgG1 isotype control; brilliant violet 605– 
conjugated Abs against CD90.2 (clone 53-2.1) and CD4 (clone RM4-
5). PE-conjugated Abs against IL-17RA (CD217, clone PAJ-17R) and 
TIM3 (clone RMT3-23) and PE-Cy–conjugated Ab against CD126 
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as the dependent variable. The independent variables were treat-
ment group and time plus interaction terms. To test for differences 
in the rate of change of log M-band, least squares means contrasts 
were performed on the treatment groups. All contrasts were adjusted 
for multiple comparisons using Tukey’s honestly significant differ-
ence (HSD). The M-band at which mice inevitably progressed was 
empirically estimated. This estimate was derived by considering 
mice longitudinally and applying a linear classifier for “progressed” 
and “not progressed” at each follow-up point. The M-band and fol-
low-up point that maximized the Youden criteria empirically was 
chosen as the optimal cutpoint. This optimal cutpoint was further 
internally cross-validated. Across all mice, the optimal M-band for 
determining progression was 0.282, with sensitivity and specificity 
of approximately 90% each.
Study approval. All animal procedures were performed in accor-
dance with protocols approved by the IACUC of the QIMR Berghofer 
Medical Research Institute.
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CD4+ and CD8+ T cells were sorted via flow cytometry (purity >98%) 
from splenocytes and lymph nodes of primary transplanted MM-bear-
ing recipients with long-term control of disease (>120 days after BMT 
progression-free survival) or naive controls. Secondary recipients 
were sacrificed 120 days after BMT.
Cell preparation, phenotyping, and flow cytometric analysis. 
Depending on the experimental design, recipient mice were sacrificed 
at weeks 2–8 after BMT, and cells from BM and spleen were collected. 
For phenotype analysis, freshly isolated cells were stained with Abs 
and analyzed by multicolor flow cytometry. For intracellular cyto-
kine staining, the collected cells were stimulated with PMA (5 μg/ml) 
and ionomycin (50 μg/ml) (Sigma-Aldrich) for 4 hours at 37°C with 
brefeldin A (BioLegend), which was included during the last 3 hours 
of culture. Cells were surfaced labeled, fixed, and permeabilized using 
the Cytofix/Cytoperm Kit (BD Biosciences), followed by staining with 
cytokine-specific Abs. To measure degranulation, based on CD107a 
expression, cells were stimulated with PMA and ionomycin in the pres-
ence of brefeldin A, monensin (BioLegend), and V450-conjugated 
CD107a Ab (BD Biosciences) for 5 hours at 37°C. To measure phos-
phorylated STAT3 levels, BM cells were collected from Vk12653-bear-
ing mice and stimulated with recombinant mouse IL-6 (50 ng/ml for 
15 minutes; BioLegend) or were unstimulated control BM cells. Cells 
were fixed and permeabilized and analyzed via flow cytometry. All 
samples were acquired on a BD LSR Fortessa (BD Biosciences), and 
cell population frequencies and protein expression were analyzed 
using FlowJo software, version 10. Dimensionality reduction was 
performed via t-SNE analysis of CD90.2+CD8+ lymphocytes downs-
ampled (5,000 cells) and pooled across all experimental groups (n = 
10 mice/group). Population clustering based on exhaustion/activation 
marker expression (CD69, TIGIT, TIM-3, DNAM-1, CD101, CD38, 
PD-1) was performed over 1,000 iterations with a perplexity of 30 
using FlowJo software, and heatmaps of individual marker expres-
sion overlaid onto t-SNE plots were generated (blue = low, red = high). 
Manual gating was performed to highlight coexpression of exhaustion 
markers as shown.
Serum IL-17A detection. Serum IL-17A was detected using an 
Enhanced Sensitivity Cytometric Bead Array Kit (BD Biosciences) 
according to the manufacturer’s instructions. Samples were acquired 
on a BD LSR Fortessa and analyzed using FCAP Array Software 
(BD Biosciences).
Exome sequencing, TCR, and RNA-Seq methods are described in 
the Supplemental Methods.
Statistics. Survival curves were plotted using Kaplan-Meier 
estimates and compared by log-rank (Mantel-Cox) test. Differenc-
es between TCR repertories were calculated by t test, and all other 
numerical variables were compared by 2-tailed Mann-Whitney U test 
for 2-sample and ANOVA for multiple-sample comparisons. Data are 
presented as the mean ± SEM, and a P value of less than 0.05 was 
considered significant. Tumor growth was modeled longitudinally 
using mixed-effects models with random intercepts and log M-band 
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